US Patent

US7709517 — Diarylhydantoin compounds

Composition of Matter · Assigned to University of California San Diego UCSD · Expires 2027-08-13 · 1y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

The patent protects diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing and using them to treat hormone refractory prostate cancer.

USPTO Abstract

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US7709517
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-08-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
University of California San Diego UCSD
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.